12:00 AM
 | 
Feb 13, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Aromasin exemestane: Additional Phase III data

Researchers at University Health Network and colleagues reported data from a subgroup of 351 postmenopausal women without osteoporosis in the double-blind, international Phase III MAP.3 trial in 4,560 postmenopausal women who were at a moderately increased risk for breast cancer showing that once-daily 25 mg Aromasin significantly reduced mean total volumetric bone mineral density (BMD) from baseline to 2 years at both the distal radius (6.1% vs. 1.8%, p<0.0001) and distal tibia vs. placebo (5% vs. 1.3%,...

Read the full 363 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >